Cas9 Stable Cell Line - GL261

The GL261 cell line is a mature mouse glioma model derived from chemically induced brain tumors in C57BL/6 mice. These cells exhibit characteristics of high-grade gliomas, including rapid proliferation, invasive growth patterns, and expression of typical glioma markers. The Cas9 Stable Cell Line - GL261 is a genetically engineered variant in which CRISPR-associated protein 9 (Cas9) is stably integrated into the GL261 genome. This modification allows for the sustained and inducible expression of the Cas9 endonuclease without transient transfection. This cell line maintains glioma specificity while providing a powerful platform for targeted genome editing.

The Cas9 Stable Cell Line - GL261 holds transformative potential in oncology and neuroscience research. Firstly, it can serve as a powerful tool for high-throughput CRISPR screening to identify novel therapeutic targets for glioblastoma. Researchers can efficiently perform gene knockout, knock-in, or transcriptional activation to investigate glioma-related pathways such as the EGFR signaling pathway, tumor suppression mechanisms, or angiogenesis regulators. Stable Cas9 expression facilitates longitudinal studies of tumor evolution and drug resistance mechanisms without the need for repeated transfections. Furthermore, this cell line can be used to accurately mimic human glioblastoma mutations in immunocompetent mouse models for preclinical immunotherapy testing. This cell line also holds immeasurable value in studying tumor microenvironment interactions, validating CRISPR-based therapies, and developing personalized treatment options through in vitro gene editing of patient-derived cells prior to transplantation.